Key clinical point: Factors predicting long-term survival with nivolumab monotherapy may inform therapy or future clinical trials.
Major finding: Excellent performance status, absence of metastases, and treatment-related adverse events were associated with better survival.
Study details: Secondary analysis of phase I trial in 270 with melanoma, RCC, or NSCLC.
Disclosures: The study and the secondary analysis were supported by Bristol-Myers Squibb. Dr. Topalian disclosed grants and travel reimbursements from Bristol-Myers Squibb and consulting fees with other entities. Multiple coauthors reported similar relationships. Four of the coauthors are Bristol-Myers Squibb employees.
Topalian SL et al. JAMA Oncology. 2019 Jul 25. doi: 10.1001/jamaoncol.2019.2187.